discontinued. according to the glaucoma research foundation, "every week of steroid use averaged over a lifetime leads to a 4% increased risk of chronic steroid glaucoma". in addition, around 90% of patients with pre-existing open angle glaucoma develop an additional adverse response to steroid treatment. treatment of uveitic glaucoma glaucoma medications, glaucoma surgery and steroids are the primary options for addressing uveitic glaucoma. approximately 30% of uveitic glaucoma patients require surgical intervention due to insufficient intraocular pressure control while on maximum medicinal therapy. available surgical interventions to treat the glaucoma in uveitic glaucoma patients pose a high risk to the eye, with a lower success rate compared to glaucoma surgeries in non-uveitic eyes. steroids for treating uveitic glaucoma patients also carry high risks. because of the risks inherent in steroid treatment and the ineffectiveness of surgical interventions for uveitic glaucoma, there is currently no approved treatment for uveitic patients who also have glaucoma. a steroid-free medication for uveitis in uveitic glaucoma patients, formulated by tarsier pharma, is currently undergoing clinical trials . challenges related to surgical treatment of uveitic glaucoma uveitic glaucoma patients respond poorly to glaucoma surgery; surgery in uveitic glaucoma patients commonly has complications. these complications are caused by either the surgical wound healing improperly or unhealthy levels of pressure inside the eye. glaucoma surgery usually leads to increased levels of inflammation in the eyes. this is an undesirable consequence, especially in uveitis patients, who already have a high tendency to develop inflammation. because of this, 80% of uveitis experts report that glaucoma surgeries for uveitic glaucoma patients are likely to fail. surgery in an eye with uveitis is associated with a higher complication rate, and in some cases surgeries such as valve implantation are too complicated to perform. prognosis for uveitic glaucoma patients about 30% of uveitis patients also develop uveitic glaucoma. uveitic glaucoma patients are at significantly higher risk for visual field loss in the long term (>5 years) compared to patients who only have uveitis. a patient who only has glaucoma (without uveitis) will, on average, become blind in one eye within 20 years of glaucoma onset. this is especially devastating given that the majority of uveitic glaucoma patients are diagnosed with uveitis at a relatively young age (in their thirties). thus developing glaucoma at a young age and the cumulative damage of uveitis flare-ups put these patients at high risk of losing their eyesight. the burden of care for uveitis glaucoma patients is also higher than that of uveitis patients without glaucoma. on average, doctors report 60% more visits from uveitic glaucoma patients than non-glaucomatous uveitis patients. doctor visits are 40% longer for patients with uveitic glaucoma than for uveitis patients without glaucoma. epidemiology according to epidemiological studies, the prevalence of uveitis is estimated at 115-316 occurrences in 100,000 people in the united states. about 30% of patients with non-infectious anterior uveitis also develop glaucoma. accordingly, 34-94 people in every 100,000 patients in the united states with uveitis will develop glaucoma. research steroid-free medication for uveitis and uveitic glaucoma a steroid-free eyedrop medication for uveitis and uveitic glaucoma patients, trs01, is undergoing clinical investigation (as of may 2022). trs01 is intended as an anti-inflammatory medication for uveitis and uveitic glaucoma that is not anticipated to contribute to elevated intraocular pressure and glaucoma. up to may 2022, two phase i/ii clinical trials testing trs01 have been completed. several dozen patients have undergone these trials. trs01 is now being investigated in a phase iii clinical trial in patients with noninfectious anterior uveitis, including some with uveitic glaucoma.